THOMAS JEFFERSON UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160139132 | Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the Neoplasm - The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression of cavcolin-1, cavcolin-2, vimentin, calponon2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm. | 05-19-2016 |
20160074389 | CAVEOLIN-1 RELATED METHODS FOR TREATING GLIOBLASTOMA WITH TEMOZOLOMIDE - This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide. | 03-17-2016 |
20160041170 | METHOD FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS - This invention relates to a method for detecting shed or circulating tumor cells in a biological fluid using labeled pituitary adenylate cyclase activating peptide or vasoactive intestinal peptide. | 02-11-2016 |
20160022180 | LONG-TERM IMPLANTABLE MONITORING SYSTEM & METHODS OF USE - Methods and systems include a long-term implantable ultra-filtrate monitoring system that uses micro-porous membranes to produce an ultra-filtrate of tissue interstitial fluid or blood plasma. The ultra-filtrate is transported through a sensor to detect a level of analyte in the ultra-filtrate. The long-term implantable fluid monitoring system thus includes a first porous catheter, a second porous catheter, a sensor configured to measure an amount of analyte in fluid, and a pump configured to move fluid through the first porous catheter to the sensor and from the sensor through the second porous catheter. | 01-28-2016 |
20150240240 | MSF REPROGRAMS MYOFIBROBLASTS TOWARD LACTATE PRODUCTION AND FUEL ANAERBOIC TUMOR GROWTH - Presented herein is a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an agent that inhibits the MSF/Cdc42/NFkB cascade in the subject's tumor-associated fibroblasts. | 08-27-2015 |
20150209422 | IMMUNIZATION WITH RABIES VIRUS VECTOR EXPRESSING FOREIGN PROTEIN ANTIGEN - An immune response in a subject is elicited by a regiment comprising immunization with an attenuated recombinant rabies virus encoding at least one foreign protein antigen, and booster immunization with the at least one foreign protein antigen in a vehicle that does not contain adjuvant. The foreign protein antigen may comprise a prion protein antigen, a cancer-associated antigens, a viral antigen, a bacterial antigens, or a protozoal antigen. The prime/boost regimen produces predominantly IgG 2A/C and IgG 2B antibodies against the foreign protein antigen, indicating a TH1 response. Rabies virus attenuation may be provided, for example, by one or more mutations in the rabies glycoprotein gene which confers attenuation of pathogenicity. | 07-30-2015 |
20150209379 | TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS - Prostate cancer and hematological neoplasms are treated by administration of (i) a compound of Formula I: wherein: R | 07-30-2015 |
20150196599 | Cell-Based Anti-Cancer Compositions With Reduced Toxicity And Methods Of Making And Using The Same - Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules. | 07-16-2015 |
20140378477 | MCT PROTEIN INHIBITOR-RELATED PROGNOSTIC AND THERAPEUTIC METHODS - This invention provides a method of identifying one or more subgroups of cancer patients that are likely to benefit from treatment with a monocarboxylate transporter (MCT) protein inhibitor comprising: (a) obtaining a sample of a cancer/tumor tissue from each of said cancer patients; (b) determining the expression level of stromal MCT4 protein in each of said samples of cancer/tumor tissue to obtain a first dataset; and (c) using the expression level of the stromal MCT4 protein from said first dataset to classify each of said sets of one or more cancer patients as stromal MCT4-positive or stromal MCT4-negative, wherein the cancer patients classified as stromal MCT4-positive are patients that are more likely to benefit from treatment with said MCT protein inhibitor. This invention also provides related methods for treating a cancer/tumor whose stromal component expresses the MCT4 protein in a patient. | 12-25-2014 |
20140363402 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION - The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue. | 12-11-2014 |
20140322705 | Cancer diagnostic and cancer therapeutic - This invention relates to methods and kits for making a prognosis of disease course in a neoplastic disease patient by determining the level, expression and/or activity of a biomarker. | 10-30-2014 |
20140294784 | Cell-Based Anti-Cancer Compositions With Reduced Toxicity And Methods Of Making And Using The Same - Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules. | 10-02-2014 |
20140271550 | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses - A CpG-modified recombinant adeno-associated viral (AAV) vector is described. The vector carries a nucleic acid molecule comprising AAV inverted terminal repeat (ITR) sequences and an exogenous gene sequence under the control of regulatory sequences which control expression of the gene product, in which the nucleic acid sequences carried by the vector are modified to significantly reduce CpG di-nucleotides such that an immune response to the vector is reduced as compared to the unmodified AAV vector. Also provided are methods and regimens for delivering transgenes using these AAV viral vectors, in which the innate immune response to the vector and/or transgene is significantly modulated. | 09-18-2014 |
20140256040 | DIAGNOSIS AND TREATMENT OF CANCERS WITH MICRORNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 09-11-2014 |
20140255518 | Treatment and Prevention of Gastrointestinal Syndrome - Compositions comprising a guanylyl cyclase C agonist in an amount effective to protect intestinal tissue against radiation or chemotherapy and methods of using such compositions to prevent GI syndrome in cancer patient undergoing radiation or chemotherapy and in individuals exposed to or susceptible to exposure to radiation are disclosed. | 09-11-2014 |
20140221496 | Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the Neoplasm - The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm. | 08-07-2014 |
20140213534 | INTESTINAL HYPERPERMEABILITY AND PREVENTION OF SYSTEMIC DISEASE - Compositions for and methods of preventing or reducing the severity intestinal hyperpermeabilization in an individual are disclosed. Compositions for and methods of preventing or reducing the severity of a disease or condition caused or exacerbated by intestinal hyperpermeabilization in an individual identified as being at risk of a disease or condition caused or exacerbated by intestinal hyperpermeabilization are also disclosed. Compositions for and methods of treating an individual who has been identified as having a disease or condition caused or exacerbated by intestinal hyperpermeabilization are additionally disclosed. | 07-31-2014 |
20140179796 | MARKERS FOR DCIS RECURRENCE: COORDINATE PTEN/RB LOSS - The technology described herein relates to compositions, kits, assays, systems and methods relating to breast cancer and the treatment thereof. | 06-26-2014 |
20140147380 | GUANYLYLCYCLASE C LIGANDS - Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed. | 05-29-2014 |
20140107390 | IMPLEMENTATION AND EXPERIMENTAL RESULTS OF REAL-TIME 4D TUMOR TRACKING USING MULTI-LEAF COLLIMATOR (MLC), AND/OR MLC-CARRIAGE (MLC-BANK), AND/OR TREATMENT TABLE (COUCH) - Methods and systems of operating a support structure and beam shaping mechanism in a manner that compensates for motion patterns exhibited by a patient, promotes comfort of the patient, and optimizes accuracy of delivery of radiotherapy to a targeted location within the patient. The support structure can be a treatment table or couch and the beam shaping mechanism can be a multi-leaf collimator (MLC), and/or an MLC-bank/-carriage. The control system can utilize algorithms for predicting tumor motion and loading condition on the table/couch during radiation therapy. | 04-17-2014 |
20140038197 | SYSTEM FOR AND METHOD OF DETERMINING CANCER PROGNOSIS AND PREDICTING RESPONSE TO THERAPY - A database for predicting clinical outcomes based upon quantitative tumor burden in lymph node samples from an individual is provided. The database comprises data sets from a plurality of individuals. The data sets include clinical outcome data and data regarding number of lymph nodes evaluated, maximum number of biomarker detected in any single node, median normalized expression levels detected across all evaluated lymph nodes and the maximum normalized expression levels detected in any evaluated lymph nodes and the database also includes stratified risk categories based upon recursive partitioning of data. A system for predicting clinical outcomes based upon quantitative tumor burden in lymph node samples from an individual is provided which includes the database linked to a data processor, an input interface and an output interface. Method of preparing a database and method for predicting clinical outcome for a test patient based upon quantitative tumor burden in lymph node samples from an individual using a system that includes the database linked to a data processor, an input interface and an output interface. The method comprises measuring quantitative tumor burden in a plurality of lymph node samples from an individual, inputting the results into the system and processing with data in the database. The results of the processing of the data is the assignment of data test patient to a stratified risk category. Output is produced that displays test patient's identity and assigned stratified risk category. | 02-06-2014 |
20140026234 | BIOMARKERS AND THEIR USES IN CANCER DETECTION AND THERAPY - Presented herein are novel protein biomarkers related to cancers with stromal components. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of diagnosis and/or prognosis of cancer. A new genetic model able to identify potential genetic suppressors and/or potential therapeutic agents for treating stromal cancers is also described. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the biomarkers and the genetic model system in clinical, diagnostic and therapeutic uses is also included. | 01-23-2014 |
20130330403 | Diagnosis And Treatment Of Cancers With MicroRNA Located In Or Near Cancer-Associated Chromosomal Features - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 12-12-2013 |
20130317083 | NON-CODING TRANSCRIPTS FOR DETERMINATION OF CELLULAR STATES - Disclosed herein are novel methods, assays and systems for determining a given state of a cell or a tissue by detecting the presence or absence of a short RNA molecule originating from (a) at least one or more exons of at least one or more protein-coding genes, or from (b) at least one or more segments of at least one or more non-coding transcripts, or from (c) both (a) and (b), in a biological sample from a subject. In some embodiments, the methods, assays and systems described herein can be used to identify an origin and/or a type of a cell or tissue, and/or distinguish a cell or tissue from another cell or tissue. In some embodiments, the methods, assays and systems described herein can also be used to diagnose a disease or disorder, or prognose a given stage and/or progression of the disease or disorder in a subject. | 11-28-2013 |
20130315923 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS - Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding | 11-28-2013 |
20130274191 | METHODS AND COMPOSITIONS FOR THERAPEUTIC MODULATION OF ALDOSTERONE LEVELS IN HEART DISEASE - The disclosure describes the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of beta-arrestin I (beta.arr-1) by the Angiotensin II (AngII) type 1 receptor (AT1R) mediates AngII-induced aldosterone production, beta-arrestin I (beta.arr-1) is a therapeutic target for heart disease. Specifically, the disclosure provides a beta.arr-1 protein fragment comprising the C-terminus of beta.arr-1 (beta.arr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of beta-arrestin (beta.arr-1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of beta.arr-1 activity and aldosterone production. | 10-17-2013 |
20130150379 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing neurodenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia. | 06-13-2013 |
20130096159 | INHIBITORS OF HUMAN 12-LIPOXYGENASE - Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R | 04-18-2013 |
20120321552 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed. | 12-20-2012 |
20120308599 | VACCINE AND METHODS OF USE AGAINST STRONGYLOIDES STERCORALIS INFECTION - The polynucleotide encoding the SSIR gene from the nematode | 12-06-2012 |
20120308583 | USE OF GCC LIGANDS - Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed. | 12-06-2012 |
20120225099 | COMPOSITIONS FOR AND METHODS OF ACTIVATING GUANYLYL CYCLASE C - Isolated non-pathogenic bacterium which comprises a nucleic acid molecule that encodes guanylyl cyclase C agonist operably linked to regulatory sequences operable in bacterium and isolated bacterium which comprises a nucleic acid molecule that encodes guanylyl cyclase C agonist operably linked to inducible regulatory sequences operable in bacterium are disclosed. Isolated culture of such bacteria and uses thereof in the prevention and treatment of colonic polyps and/or colorectal cancer as well as methods of activating guanylyl cyclase C in humans are disclosed. | 09-06-2012 |
20120100116 | NEURON GENERATION, REGENERATION AND PROTECTION - The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress. | 04-26-2012 |
20120064039 | Use of Guanylyl Cyclase C Agonists to Suppress Appetite - Compositions comprising a guanylyl cyclase C agonist formulated for sustained specific release of an amount effective to suppress appetite when administered orally to an individual are disclosed. Compositions comprising a guanylyl cyclase C agonist formulated for intravenous delivery in an amount effective to suppress appetite when administered intravenously to an individual are also disclosed. Methods of suppressing appetite in an individual are disclosed. | 03-15-2012 |
20120015368 | BIOMARKERS FOR EARLY DIAGNOSIS OF SYSTEMIC TISSUE FIBROSIS - Embodiments of the invention provides methods, devices and kits for determining the likelihood of an individual having an active fibrotic condition and/or early diagnosis, and subsequently prognosis evaluation of an individual having an active fibrotic condition such as systemic sclerosis (SSc) and/or nephrogenic systemic fibrosis (NSF) by measuring the levels of several biomarkers: α-enolase (ENO1), reticulocalbin 3 (RCN-3), alpha smooth muscle actin (α-SMA), reticulocalbin 1 (RCN-1) and pigment epithelium-derived factor (PEDF) in the individual. | 01-19-2012 |
20110260726 | PHASE LABELING USING SENSITIVITY ENCODING: DATA ACQUISITION AND IMAGE RECONSTRUCTION FOR GEOMETRIC DISTORTION CORRECTION IN EPI - A phase labeling using sensitivity encoding system and method for correcting geometric distortion caused by magnetic field inhomogeneity in echo planar imaging (EPI) uses local phase shifts derived directly from the EPI measurement itself, without the need for extra field map scans or coil sensitivity maps. The system and method employs parallel imaging and k-space trajectory modification to produce multiple images from a single acquisition. The EPI measurement is also used to derive sensitivity maps for parallel imaging reconstruction. The derived phase shifts are retrospectively applied to the EPI measurement for correction of geometric distortion in the measurement itself. | 10-27-2011 |
20110250228 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. | 10-13-2011 |
20110244570 | VOLUME EXCLUSION AGENT TO ENHANCE FORMATION OF EXTRACELLULAR MATRIX - A method of enhancing the formation of extracellular matrix in culture. Cells in culture secrete most of the collagen into the media as unprocessed procollagen, i.e., the cells do not convert procollagen to collagen. In contrast, normal extracellular matrix deposition involves procollagen processing to collagen, fibril assembly and deposition into the cell layer to form a collagenous extracellular matrix. The addition of certain growth factors and the addition of a thin layer of a certain volume exclusion agent on top of the cells dramatically enhances the conversion of procollagen to collagen and will increase the amount of collagen and extracellular matrix associated with the cells. This invention advances bioengineering of connective tissues for medical applications that require an extensive and functional extracellular matrix with high tensile strength such as those in the cornea stroma, skin, tendons, ligaments, articular cartilage and the intervertebral disks. | 10-06-2011 |
20110206736 | Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same - Nucleic acid molecules comprising a nucleotide sequence that encodes a chimeric protein are disclosed. The chimeric proteins comprise at least one epitope of a mucosally restricted antigen, at least one CD4+ helper epitope, and, optionally, a secretion sequence. Chimeric proteins that comprise at least one epitope of a mucosally restricted antigen, at least one CD4+helper epitope and, optionally a secretion sequence are also disclosed. Compositions including pharmaceutical compositions and injectables comprising nucleic acid molecule and proteins are disclosed. Methods of treating individuals diagnosed with cancer of a mucosal tissue and methods of preventing cancer of a mucosal tissue are disclosed. | 08-25-2011 |
20110195415 | GUANYLYL CYCLASE C QRT-PCR - Methods, kits, compositions and systems for detecting the level of GCC encoding mRNA present in a sample using quantitative (q) RT-PCR are disclosed. The methods, kits, compositions and systems may be used to detect metastasis in patients diagnosed with primary colorectal, gastric or esophageal cancer, to predict the risk of occurrence of relapse in patients diagnosed with primary colorectal, gastric or esophageal cancer, and to diagnose Barrett's esophagus. | 08-11-2011 |
20110184019 | Long chain N-Alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 07-28-2011 |
20110104050 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin - Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed. | 05-05-2011 |
20110064764 | Attenuated Live Triple G Protein Recombinant Rabies Virus Vaccine for Pre- and Post-Exposure Prophylaxis of Rabies - The invention provides a recombinant rabies viruses comprising three copies of a mutated G gene wherein each G gene encodes a rabies virus glycoprotein having the amino acid 194 mutated to a serine and the amino acid 333 is mutated to a glutamic acid. The recombinant rabies virus is nonpathogenic in immunodeficient mammals and can be used in a vaccine to induce an immune response protect mammals from infection by rabies virus as well as clear a pre-existing rabies virus infection from neural tissues. | 03-17-2011 |
20110008344 | FUSION PARTNER CELL LINE FOR PREPARATION OF HYBRID CELLS EXPRESSING HUMAN ANTIBODIES - This invention relates to a novel fusion partner cell line that ectopically expresses IL-6 and TERT termed B5-6T, and to methods for making the B5-6T fusion partner cell line. The B5-6T fusion partner cell line can be fused with B-lymphocytes to generate hybridomas that secrete human monoclonal antibodies. | 01-13-2011 |
20110002937 | METHOD OF MAKING HYBRID CELLS THAT EXPRESS USEFUL ANTIBODIES - This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention. | 01-06-2011 |
20100297264 | BOWEL PURGATIVE AND USES THEREOF - The present invention is directed to a dry composition for admixture with water for oral administration to a mammal and methods of using the composition for cleansing the bowel of a mammal in need thereof. | 11-25-2010 |
20100285480 | TCL-1 GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS - The present invention relates to nucleotide sequences of TCL-1 genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The TCL-1 gene sequence is preferentially expressed early in T and B lymphocyte differentiation. The present invention further relates to the use of TCL-1 genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with chromosomal abnormalities. | 11-11-2010 |
20100272711 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES - The present invention is directed to a pharmaceutical composition, and methods of use thereof, comprising at least one agent which target multiple adenosine receptors (AR) simultaneously in a stoichiometric relationship (i.e. each AR receptor is targeted to an equal extent). Aspects of the present invention relate to pharmaceutical compositions, and uses thereof, comprising at least one agent which co-activates an A | 10-28-2010 |
20100247560 | MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF - Modified polypeptides based on the | 09-30-2010 |
20100234241 | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 09-16-2010 |
20100222555 | Monoclonal antibodies that neutralize botulinum neurotoxin - This invention provides antibodies that specifically bind to botulinum neurotoxin type A (BoNT/A) and/or botulinum neurotoxin type B (BoNT/B) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. Also included in the invention are diagnostic and therapeutic assays directed to botulinum neurotoxins. | 09-02-2010 |
20100221290 | MIXED HAPTENIZED TUMOR CELLS AND EXTRACTS AND METHODS OF TREATING OR SCREENING FOR CANCER - This invention relates to compositions comprising multi-haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such multi-haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma and ovarian adenocarcinoma cells are multi-haptenized, wherein the tumor cells are differentially haptenized either with a dinitrophenyl group coupled to s-amino groups, or with a sulfanilic acid group coupled to aromatic side chains of histidine and tyrosine. A method of SA-haptenization is also provided. | 09-02-2010 |
20100203544 | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER ASSOCIATED CHROMOSOMAL FEATURES - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 08-12-2010 |
20100192235 | HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA MODELED IN MOUSE BY TARGETED TCL1 EXPRESSION - Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals provide a useful animal model system for human B cell chronic lymphocytic leukemia. | 07-29-2010 |
20100190840 | TISSUE SPECIFIC GENE THERAPY TREATMENT - The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca | 07-29-2010 |
20100173319 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND THERAPY - The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases. | 07-08-2010 |
20100137365 | Long chain N-alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C | 06-03-2010 |
20100056445 | ADIPONECTIN FOR THE TREATMENT AND DIAGNOSIS OF ALBUMINURIA - Disclosed are methods relating to the treatment and/or prevention of kidney disorders, especially kidney disorders characterized by or involving albuminuria. Methods described include the administration of an adiponectin polypeptide or a nucleic acid encoding such a polypeptide to treat or prevent the development of albuminuria. Also described are methods in which adiponectin is measured as a predictor of a subject's likelihood of having or developing a kidney disorder characterized by or involving albuminuria. Also described are methods of treating or preventing a kidney disorder involving administering an AMPK agonist and/or an inhibitor of Nox4 activity. | 03-04-2010 |
20100048479 | ADRENAL GRK2 ACTIVITY AS A THERAPEUTIC TARGET FOR HEART FAILURE - The present invention relates to compositions and methods for the treatment of failing hearts. More specifically, the present invention provides for the inhibition of G-protein coupled receptor kinase 2 activity in the adrenal gland, which, for example, decreases catecholamine secretion and the sympathetic burden of the failing heart, thereby improving the cardiac adrenergic/inotropic reserve and overall contractile function. | 02-25-2010 |
20100047798 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME - The present invention relates to methods for identify subjects for responsiveness to adenosine agonist treatment. Another aspect of the present invention relates to methods to predict a relative infarct size in response to ischemia reperfusion injury. In particular, the present invention relates to methods for to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences such as mutations and/or polymorphisms in the human A1 adenosine receptor (A1-AR) gene that alters the stability of the A1-AR mRNA. Other aspect of the present invention relates to methods to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences, such as mutations and/or polymorphisms in the human A3 adenosine receptor (A3-AR) gene that alters the A3-AR protein function. Other aspect of the present invention also relate to kits and assays to detect sequence differences in the human A1 adenosine receptor (A1-AR) gene and/or A3 adenosine receptor (A3-AR) gene. | 02-25-2010 |
20100029570 | PEPTIDE AND TREATMENT FOR HIV-1 INFECTION - A compound of the formula X | 02-04-2010 |
20100029568 | TIGHTER-BINDING C-PEPTIDE INHIBITORS OF HIV-1 ENTRY - The invention provides compositions and methods for the treatment of HIV infection, inhibition against drug-resistant strains of HIV-1 and methods of enhancing the anti-HIV potency of peptide inhibitors against drug-resistant strains of HIV-1. In particular, oligomeric C-peptide inhibitors for inhibiting HIV entry into host cells are disclosed. | 02-04-2010 |
20100021915 | HIGH THROUGHPUT DNA SEQUENCING METHOD AND APPARATUS - The present invention relates to a method for high throughput nucleic acid sequencing using a multi-bead flow cell and pyrophosphate sequencing, a sequencer capable of performing this method, and a kit of the pyrophosphate sequencing reagents. | 01-28-2010 |
20100008964 | ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. | 01-14-2010 |
20100003269 | METHODS AND USES OF CAULIFLOWER AND COLLARD FOR RECOMBINANT PROTEIN PRODUCTION - The present invention relates to a method for the generation of transgenic | 01-07-2010 |
20090299357 | CRYONEEDLE AND CRYOTHERAPHY SYSTEM - A device and system for cryogenically treating tissue having an external cryoneedle including an outer housing having a proximal end, a proximal portion, a distal portion and a distal end. The proximal portion of the outer housing is coated with a first material and the distal portion of the outer housing is coated with a second material. The distal end is sealed with a third material. The first material has different temperature conductive properties than the second and third materials. An internal cryoneedle having a first and second end is axially disposed within the external cryoneedle. The first end of the internal cryoneedle is in communication with the sealed distal end of the external cryoneedle and the second end of the internal cryoneedle being in fluid communication with a cryogen source. | 12-03-2009 |
20090123533 | Compositions and methods for cancer diagnosis and therapy - The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases. | 05-14-2009 |
20090053248 | Compositions and methods for transepithelial molecular transport - The invention relates to fragments of | 02-26-2009 |
20090035347 | ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. | 02-05-2009 |
20090023977 | Method of Treatment to Improve Concentration and/or Memory in a Subject in Need Thereof - The present invention is directed to a method of treatment to improve at least one of concentration, memory, cognitive performance, and stress-relief in a subject in need thereof by controlled administration of synchronized flashes of light and pulsed tones. | 01-22-2009 |
20080286799 | METHODS OF AND KITS AND COMPOSITIONS FOR DIAGNOSING COLORECTAL TUMORS... - In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed. | 11-20-2008 |
20080280829 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing metabolic bone diseases and disorders by inhibition of Lp-PLA | 11-13-2008 |
20080279846 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia. | 11-13-2008 |
20080256650 | Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression - Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals provide a useful animal model system for human B cell chronic lymphocytic leukemia. | 10-16-2008 |